<div><p><strong>Mulching films used in agriculture gradually break down and can become a significant source of microplastics in soils. A new study shows that these particles affect not only soil structure but also microbial life and nitrogen cycling.</strong></p><p><i>“We wanted to understand how microplastics from both conventional and biodegradable mulching films influence soil properties, microbial diversity and functions in real conditions,”</i> explains <strong>Klára Šmídová</strong>, the study’s co-author . <i>“That’s why we added realistic amounts of microplastics to soils in experimental plots in Finland, Germany, and Spain, monitored them over two growing seasons, and compared them with the control plots.”</i></p><p>The results revealed that microplastics alter soil characteristics and microbial communities, although not always in the same way. <i>“ However, a consistent finding was the decline in microbial activity associated with key processes, including nitrogen cycling, with negative effects increasing at higher microplastic concentrations and becoming more pronounced in the second year,” </i>Šmídová adds. Because the microplastic levels used in the study reflect amounts already found in European soils, the findings highlight real risks to soil health. <i>“We also found that the effects were stronger in southern than in northern Europe, likely due to differences in climate and soil conditions. This means that protecting soils from plastic pollution will require region-specific risk assessments,”</i> she says.</p><p>Over 60% of European soils are estimated to be unhealthy, with ongoing degradation driven by unsustainable land use, contamination, climate change, and extreme weather events. In response, the EU Parliament adopted the Soil Monitoring Law in October 2025, aiming to achieve healthy soils across Europe by 2050. <i>“The law highlights the role of soil health in food security, water quality, and climate objectives, and establishes consistent soil monitoring across Member States. It includes measures to support farmers and foresters, while also creating a public list of potentially contaminated sites and an indicative watch list of emerging soil contaminants,” </i>explains Klára Šmídová.</p><p>The project brought together 19 research groups across Europe. <i>“After each season, hundreds of samples were colle cted and sent to partners for analysis. This paper focuses on soil properties, microbial diversity, and greenhouse gas emissions. Two more manuscripts—on plastic additives and microplastic fate, and on soil invertebrates—are in preparation. Together, they will give us a complete picture of how agricultural microplastics affect soil ecosystems,” </i>concludes Klára Šmídová.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/RECETOX_Vysledky_nove_studie_ukazaly_ze_mikroplasty_meni_vlastnosti_pudy_a_mikrobialni_spolecenstva_i_v_realnych_podminkach_6ee3413a7b.jpg" alt="RECETOX: New Study Reveals How Agricultural Plastics Impact Soil Health In Real Conditions" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_RECETOX_Vysledky_nove_studie_ukazaly_ze_mikroplasty_meni_vlastnosti_pudy_a_mikrobialni_spolecenstva_i_v_realnych_podminkach_6ee3413a7b.jpg 171w," sizes="100vw" width="738" height="674"></p><blockquote><h4><strong>The Original article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://www.sciencedirect.com/science/article/pii/S0269749125015866?via%3Dihub#sec2"><span><strong>Conventional and biodegradable agricultural microplastics: effects on soil properties and microbial functions across a European pedoclimatic gradient</strong></span></a></h4><p>Šmídová K., Soinne H., Kim S. W., Tirronniemi J., Meffe R., Redondo-Hasselerharm P. E., Braun M., Rillig M. C., Fritze H., Adamczyk B., Nikama J., Kaseva J., Saartama V., Amelung W., Hurley R., Hofman J., Nizzetto L., Selonen S., Velmala S.</p><p>Environ. Pollut. 386 (2025) 127212</p><p><a href="DOI:%2010.1016/j.envpol.2025.127212"><span>DOI:&nbsp;10.1016/j.envpol.2025.127212</span></a></p><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><h4><strong>Abstract</strong></h4><div><p>Agricultural plastics like mulching films may become a major source of microplastic (MP) soil contamination during their degradation and fragmentation. This study investigates the effects of agricultural MPs from conventional (linear low-density polyethylene, PE) and biodegradable (starch-blended polybutylene adipate co-terephthalate, PBAT-BD) mulching films on soil physicochemical properties, aggregation, microbial diversity and functions, litter decomposition, and greenhouse gases emissions (GHG). For this purpose, MPs were mixed into soils at realistic MP concentrations of 0.005&nbsp;% and 0.05&nbsp;% (w/w) in 2022 on experimental plots in three EU countries representing different pedoclimatic conditions (Finland, Germany and Spain), followed by monitoring of the above-mentioned variables in the subsequent growing seasons 2022 and 2023. We found several significant MP-induced effects for soil properties, aggregation, microbial diversity, litter decomposition, and GHG, but the effect endpoints were less pronounced or varied considerably. Contrarily, microbial activity, contributing to soil functions such as nitrogen cycling, was consistently reduced by both conventional and biodegradable MPs. The reductions were more pronounced after the second season and for the higher MP treatment. As the higher MP concentration (i.e., 0.05&nbsp;% w/w) is environmentally relevant in Europe, our findings emphasize the potential effects of environmentally relevant MP concentrations on soil health. Furthermore, the effects increased from north to south, probably modulated by varying pedoclimatic conditions, inducing reflection of a need for regionally tailored risk</p></div></div>

New Study Reveals How Agricultural Plastics Impact Soil Health In Real Conditions

<h3><strong>Charged for Action: The Hidden Secrets of AEX Oligonucleotide Analysis</strong></h3><p><strong>Oligonucleotides—short, well-defined fragments of DNA or RNA—have become indispensable tools in modern life sciences. They underpin cutting-edge applications in molecular diagnostics, gene therapy, and pharmaceutical development. Before oligonucleotides can be confidently used in research or clinical settings, however, their quality must be rigorously assessed. Purity, sequence integrity, length distribution, and chemical modifications all play a decisive role in their performance.</strong></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Oligos_Made_Easy_Part_2_AEX_2_45eee54fa0.jpg" alt="KNAUER: Oligos Made Easy - Part 2: AEX" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Oligos_Made_Easy_Part_2_AEX_2_45eee54fa0.jpg 245w," sizes="100vw" width="1534" height="711"></p><p>Among the analytical techniques available today, <strong>anion exchange chromatography (AEX)</strong> stands out as a robust and highly informative method for characterizing oligonucleotides. By exploiting their intrinsic negative charge, AEX provides detailed insight into product composition and impurity profiles that are difficult to obtain by other approaches.</p><blockquote><p><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/6808"><strong>Part 1 of the Oligos series: A Practical Guide to Oligonucleotide Production – From Concept to Final Product</strong></a></p></blockquote><h4><strong>How Scientists Read Oligonucleotides Using Charge</strong></h4><p>At the core of AEX lies a simple but powerful principle: oligonucleotides carry a negatively charged phosphate backbone. This charge increases in a predictable way with strand length and, to a lesser extent, sequence composition. Anion exchange chromatography uses this property to separate oligonucleotides based on differences in charge strength and interaction with a positively charged stationary phase.</p><p>As a result, AEX has become one of the most widely used analytical tools for evaluating oligonucleotide quality. It allows scientists to distinguish full-length products from truncated species, degradation products, or closely related variants—often with single-nucleotide resolution.</p><h4><strong>Why Ion Exchange Works: Binding, Retention, and Release</strong></h4><p>Ion exchange chromatography (IEX) relies on electrostatic interactions between analytes and a charged stationary phase. In the case of oligonucleotides, <strong>anion exchange</strong> is used, where negatively charged molecules interact with positively charged functional groups on the resin—most commonly quaternary amines.</p><p>The system consists of two main components:</p><ul><li><strong>Stationary phase:</strong> A positively charged resin that binds anionic analytes.</li><li><strong>Mobile phase:</strong> An aqueous buffer system, typically combined with a salt gradient, that controls both pH and elution strength.</li></ul><p>Retention in AEX is governed primarily by charge. Molecules with weaker overall charge interact less strongly with the stationary phase and elute earlier, while more highly charged oligonucleotides bind more tightly and require stronger elution conditions.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_1_IEX_overview_including_elution_order_dependency_on_analyte_charge_3419ad3075.jpg" alt="KNAUER: Oligos Made Easy - Part 2 AEX: Figure 1 IEX overview including elution order dependency on analyte charge." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_1_IEX_overview_including_elution_order_dependency_on_analyte_charge_3419ad3075.jpg 245w," sizes="100vw" width="1583" height="654"></p><h4><strong>The Five-Step Workflow of Ion Exchange Chromatography</strong></h4><p>AEX separations generally follow a well-established sequence of steps:</p><ol><li><strong>Column equilibration</strong><br>The column is conditioned with the starting buffer until the baseline and pH are stable. This ensures that all charged sites on the resin are ready for interaction.</li><li><strong>Sample loading</strong><br>Samples, prepared in the starting buffer, are introduced under conditions that promote binding of the target oligonucleotides while minimizing retention of unwanted impurities.</li><li><strong>Washing</strong><br>The column is washed with the starting buffer to remove uncharged or weakly interacting components. The baseline stabilizes as these species are flushed away.</li><li><strong>Elution</strong><br>Bound oligonucleotides are released using a salt or pH gradient. Increasing ionic strength introduces competing ions that displace the analytes from the resin. Weakly bound species elute first; strongly charged oligonucleotides elute later.</li><li><strong>Regeneration and re-equilibration</strong><br>A high-salt buffer removes any remaining bound material. The column is then returned to starting conditions in preparation for the next analysis.</li></ol><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_2_Five_steps_of_IEX_procedure_in_blue_outlined_using_an_example_chromatogram_in_red_38dd70b1b1.jpg" alt="KNAUER: Oligos Made Easy - Part 2 AEX: Figure 2  Five steps of IEX procedure (in blue), outlined using an example chromatogram (in red)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_2_Five_steps_of_IEX_procedure_in_blue_outlined_using_an_example_chromatogram_in_red_38dd70b1b1.jpg 245w," sizes="100vw" width="1583" height="674"></p><h4><strong>Why AEX Is Especially Effective for Oligonucleotides</strong></h4><p>The repeating phosphate backbone of oligonucleotides gives rise to a strong and uniform anionic character across a wide pH range (typically pH 7–9). This makes oligonucleotides exceptionally well suited for anion exchange separations.</p><p>Key factors influencing AEX behavior include:</p><ul><li><strong>Charge density:</strong> Longer oligonucleotides carry more negative charges and therefore exhibit stronger retention.</li><li><strong>Resin chemistry:</strong> Strong and weak anion exchangers differ in functional groups and pH stability, influencing selectivity and robustness.</li><li><strong>Buffer composition:</strong> The choice of buffering ions and salt gradients directly affects elution strength and resolution.</li></ul><p>Salt gradients—commonly based on chloride ions—compete with the oligonucleotide backbone for binding sites on the resin. By carefully tuning gradient slope and composition, analysts can achieve highly reproducible and finely resolved separations.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_3_Ionic_interactions_and_p_H_influence_on_Anion_Exchange_Chromatography_AEX_612e231ba4.jpg" alt="KNAUER: Oligos Made Easy - Part 2 AEX: Figure 3 Ionic interactions and pH influence on Anion Exchange Chromatography (AEX)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_3_Ionic_interactions_and_p_H_influence_on_Anion_Exchange_Chromatography_AEX_612e231ba4.jpg 245w," sizes="100vw" width="1547" height="593"></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_4_AEX_buffer_selection_and_gradient_strategy_chromatogram_with_red_buffer_gradient_curve_53fd1bb11b.jpg" alt="KNAUER: Oligos Made Easy - Part 2 AEX: Figure 4 AEX buffer selection and gradient strategy (chromatogram with red buffer gradient curve)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_4_AEX_buffer_selection_and_gradient_strategy_chromatogram_with_red_buffer_gradient_curve_53fd1bb11b.jpg 245w," sizes="100vw" width="1600" height="327"></p><h4><strong>AEX as the Gold Standard for Oligonucleotide Separation</strong></h4><p>Anion exchange chromatography has become the method of choice for both analytical and preparative oligonucleotide workflows. Its advantages include:</p><ul><li><strong>High resolving power:</strong> Closely related impurities, including n–1 or n–2 species, can often be separated and quantified.</li><li><strong>Predictable retention behavior:</strong> In many cases, retention time correlates linearly with oligonucleotide length, simplifying identification.</li><li><strong>Compatibility with modified oligonucleotides:</strong> Even chemically modified sequences retain their anionic nature, allowing AEX to resolve both products and related impurities.</li><li><strong>Excellent control via gradient elution:</strong> Salt gradients provide precise tuning of selectivity and resolution.</li></ul><p>Typically, shorter or degraded oligonucleotides elute at lower ionic strength, while full-length products with higher charge density appear later in the chromatogram.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_5_AEX_Advantages_and_Challenges_7835521e34.jpg" alt="KNAUER: Oligos Made Easy - Part 2 AEX: Figure 5 AEX Advantages and Challenges." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Oligos_Made_Easy_Part_2_AEX_Figure_5_AEX_Advantages_and_Challenges_7835521e34.jpg 245w," sizes="100vw" width="1535" height="707"></p><h4><strong>Final Perspective: Mastering AEX with Confidence</strong></h4><p>Anion exchange chromatography may appear complex at first, but with thoughtful optimization of pH, buffer composition, and gradient conditions, it becomes a highly precise and reliable tool for oligonucleotide analysis. When properly applied, AEX delivers sharp peaks, excellent resolution, and robust performance—even for challenging sequences and modifications.</p><p>For laboratories developing or refining oligonucleotide workflows, AEX offers both analytical depth and operational confidence.</p><blockquote><p>If you would like to discuss AEX method development or optimization for oligonucleotides, feel free to contact us at <strong>sales@knauer.net</strong>. More insights into practical oligonucleotide analysis will follow in our <i>“Oligos Made Easy”</i> series.</p><p>For technical questions or in-depth discussion, the author can be reached at <strong>kindler@knauer.net</strong></p></blockquote>

Oligos Made Easy - Part 2: AEX

News from LabRulezLCMS Library - Week 07, 2026

Article

Application

Plastics

Environment

Science and research

Poster

RECETOX (Research Centre for Toxic Compounds in the Environment) is an independent department of the Faculty of Science of Masaryk University in Brno, which has been established in 1983. RECETOX is focused on the research and education in cross-cutting area of Environment and Health. It addresses interactions among chemicals, environment, and biological systems, including consequences at local, regional, and global levels.

RECETOX - Centrum pro výzkum toxických látek v prostředí

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

The Analytical Scientist

Agilent Technologies

Technology Networks

Bruker

<p><strong>Join us for an exclusive one-day hybrid event, here we&#39;ll explore the latest trends and innovations in microplastics analysis. The morning session will be live-streamed and recorded, allowing virtual  articipation for those unable to attend in person.</strong></p>
<p>We are excited to invite you to a special <strong>hybrid event</strong> in partnership with <strong>i3 Membrane</strong>, where we will delve into the latest trends and innovations in microplastics analysis. Whether you join us in person or virtually, you’ll gain invaluable insights and hands-on experience.</p>
<p><strong>Event also available in live stream</strong></p>
<h3><strong>Agenda:</strong></h3>
<ul>
<li><p><strong>Morning session:</strong> Gain key insights into <a href="https://icpms.labrulez.com/library?mainauthorItems=10&amp;search=microplastics+analysis"><strong>microplastics analysis</strong></a>, as well as <a href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=PFAS"><strong>PFAS</strong></a> and other environmental contaminants, through engaging presentations by top researchers and industry experts.</p>
</li>
<li><p><strong>Afternoon session:</strong> Participate in interactive workshops designed to enhance your practical skills in sample preparation. This provides a unique opportunity to master advanced techniques and methodologies under the guidance of professionals. Attend a live demo on the IR QCL-based <a href="https://icpms.labrulez.com/library?mainauthorItems=10&amp;search=8700+LDIR"><strong>8700 LDIR</strong></a>. Additionally, enjoy a guided laboratory tour offering an exclusive glimpse into the state-of-the-art facilities at the HEREON campus.</p>
</li>
</ul>
<h5>9:15 a.m. - Welcome</h5>
<h5>9:20 a.m. - <strong>From Macroplastics to Mesoplastics: Challenges and Solutions</strong></h5>
<ul>
<li>Dr. Marion Börger, Agilent Technologies,</li>
<li>Dr. Andreas Kerstan, Agilent Technologies</li>
</ul>
<h5>9:40 a.m. - <strong>i3 Membrane Session: Filter Membranes/Packaging - Jacobs</strong></h5>
<ul>
<li>Kathrin Hahn, i3 Membrane</li>
</ul>
<h5>10:00 a.m. - <strong>Exploring Microplastic Sources and Distribution in Australian Soils</strong></h5>
<ul>
<li>Subharthe Samandra, University of Melbourne</li>
</ul>
<h5>10:20 a.m. - <strong>Advancing Analysis: Eurofins&#39; Path to ISO 17025 Accreditation for Microplastics Testing</strong></h5>
<ul>
<li>Julia Jäger, Eurofins</li>
</ul>
<h5>10:40 a.m. - Coffee Break</h5>
<h5>11:00 a.m. - <strong>Validation and Application of LDIR Imaging to Analyze Microplastics in Marine Samples</strong></h5>
<ul>
<li>Lars Hildebrandt, Hereon</li>
</ul>
<h5>11:20 a.m. - <strong>Applying Multiple Analytical Techniques to Answer Open Questions About Offshore Wind</strong></h5>
<ul>
<li>Alexa Zonderman, Hereon</li>
</ul>
<h5>11:40 a.m. - <strong>Sample-Based Subsampling Strategies to Analyze Large Quantities of Particles in LDIR</strong></h5>
<ul>
<li>Manuel Andrade, University La Coruna</li>
</ul>
<h5>12:00 p.m. - <strong>Beyond the Surface: Spotlight on Plastic [Metal(loid)] Additive Leaching and Unseen Contaminants</strong></h5>
<ul>
<li>Ole Klein, Hereon</li>
</ul>
<h5>12:20 p.m. - <strong>Microplastics back in food- Advantages of Thermal Desorption for a wide range of Samples</strong></h5>
<h5>12:40 p.m. - <strong>Struggling with Solvent Effects During the Analysis of PFAS</strong></h5>
<ul>
<li>Dr. Axel Ritter, Agilent Technologies</li>
</ul>
<h5>1:00 p.m. - Lunch Break</h5>
<h5>2:00 p.m. - <strong>An Analytical Toolbox to Unravel PFAS Source Fingerprints</strong></h5>
<ul>
<li>Frank Menger, Hereon</li>
</ul>
<h5>2:20 p.m. - <strong>LDIR for Assessment of Microplastics in the VAMAS Ring Trial and Tissue in a Murine Infection Model</strong></h5>
<ul>
<li>Christoph Krafft, IPHT</li>
</ul>
<h5>2:40 p.m. - <strong>Label-Free Infrared Spectroscopic Micro- and Nanoplastics Detection in Complex Matrices</strong></h5>
<ul>
<li>Markus Brandstetter, Recendt</li>
</ul>
<h5>3:00 p.m. - <strong>Break in Dividing the Guests into Subgroups</strong></h5>
<h5>3:10 p.m. - <strong>Lab Visits: Organic Lab, Microplastics Lab, Sample Prep, LDIR, and Other Techniques</strong></h5>
<h5>4:50 p.m. - Wrap up</h5>
<h3><strong>Meeting Information</strong></h3>
<ul>
<li><p><strong>Date:</strong> 29 October 2024</p>
</li>
<li><p><strong>Time:</strong> 9:00 a.m. to 4:50 p.m. CEST</p>
</li>
<li><p><strong>Location:</strong> GITZ GmbH, Max-Planck-Straße 2, 21502 Geesthacht, Germany </p>
</li>
<li><p><strong>Meals included:</strong> Enjoy complimentary lunch and snacks during the event.</p>
</li>
</ul>
<p><strong>Limited spots available!</strong> Hurry, to secure yours today.</p>
<blockquote>
<p><a href="https://explore.agilent.com/microplameeting24#form"><strong>Secure your spot</strong></a></p>
</blockquote>


Agilent Microplastics Meeting 2024

We'll explore the latest trends and innovations in microplastics analysis.

<p><strong>We’ll explore how outlier setup can help you focus on samples and compounds that require your attention, ensuring accurate and reliable results.</strong></p><p>Additionally, you’ll learn how viewing compounds and calibration at a glance can expedite data review, making the process faster and more intuitive.</p><p>Finally, we’ll demonstrate how easily you can summarize your results in comprehensive reports or export them to Excel, streamlining your workflow and enhancing productivity.</p><p>Don’t miss this opportunity to enhance your data analysis skills with MassHunter Quant!</p><blockquote><p><strong>Presenter:</strong> Peter Kornas (LC/MS Applikationsspezialist, Agilent Technologies)</p><p>Peter Kornas has more than 10 years of experience in the development and validation of analytical methods for the determination of pesticides, mycotoxins and contaminants using LC/MS/MS. Before joining Agilent as an LC/MS application specialist in 2018, he worked as an analytical chemist in the food industry. During this time, he was responsible for the development and validation of analytical methods and worked in close coordination with Regulatory Affairs to ensure compliance with the legal requirements of the LC/MS method portfolio.</p></blockquote>

Agilent Technologies: MassHunter Masterclass Months

MassHunter Quant – A Fast and Easy Way from Data to Results

Join us and discover how quickly a quantitation method can be set up, enabling efficient data processing.

<p><strong>Join us for an insightful webinar where we will explore the critical aspects of differentiating good from bad data and how this distinction can significantly influence your results. From screening to quantification, discover the value of targeted data analysis workflows using non-targeted data with our innovative software and hardware.</strong></p><p>Find by Formula algorithm. Learn to identify the most suitable MS/MS approach for your experiments, initiate quantitation for your compounds of interest, and incorporate retention times (RTs) and MS/MS spectra into a custom database and library.</p><p>This session is designed to enhance your understanding and application of Q-TOF data analysis, ensuring robust and reliable outcomes.</p><blockquote><p><strong>Presenter:</strong> Hannah Florance (Agilent Technologies)</p><p>Hannah has had multiple roles in the life sciences, starting as a protein chemist, before moving into proteomics and then metabolomics. A major part of her time working in academia involved running LC and GCMS core facilities supporting projects ranging from synthetic biology to cancer research. She is currently an LCMS applications specialist for Agilent.<br><br><strong>Presenter:</strong> Stefan Schaebler (Application Specialist LC/MS, Agilent Technologies)</p><p>Stefan completed his PhD in Biology, specializing in LC-MS-based lipidomics and metabolomics. Following his doctoral studies, he joined Agilent Technologies as an LC/MS Application Specialist. In this role, Stefan focuses on small molecule applications using LC-QTOF, with a strong emphasis on software tools and data interpretation.</p></blockquote>

MassHunter Qual – The Solid Pillar in Q-TOF Data Analysis

We will explore the critical aspects of differentiating good from bad data and how this distinction can significantly influence your results.

<p><strong>Are you ready to take your LC-TQ troubleshooting skills to the next level?</strong></p><p><strong>Whether you’re a seasoned expert or just starting out, this session is packed with valuable insights and practical tips to help you maintain and optimize your system’s performance.</strong></p><h5><strong>What to Expect:</strong></h5><p>Unlock the Secrets of LC-TQ: Get a first introduction to troubleshooting and understand why it’s crucial for maintaining optimal performance.</p><ul><li><strong>Tackle Common Challenges:</strong> Learn how to identify and resolve issues like contamination, ion suppression, and clogged nebulizers.</li><li><strong>Preventive Maintenance Tips:</strong> Discover best practices for keeping your system in top shape, including the importance of regular check tunes and effective issue reporting.</li><li>Get useful resources to deepen your knowledge about LC-TQ troubleshooting and guides on where to start</li></ul><p>Come with any questions you might have about troubleshooting your LC/MS Triple Quadrupole system and submit them for the Q&amp;A session.</p><p>We look forward to welcoming you at this webinar!&nbsp;</p><p><strong>Presenter:</strong> Srinivasa Chakravarthy (Field System Specialist &amp; Certified Instructor (Single and Triple Quad LC/MS), Agilent Technologies)</p>

Agilent Technologies: Troubleshoot Your Misbehaving Triple Quadrupole LC/MS

Troubleshoot Your Misbehaving Triple Quadrupole LC/MS

Are you ready to take your LC-TQ troubleshooting skills to the next level?

<div><p><strong>To unravel the functions of the vast universe of small molecules in human biology it is essential to first detect and quantify these molecules—a task carried out by the field of metabolomics. In traditional liquid chromatography-mass spectrometry (LC-MS)-based metabolomics, quantitative analysis is divided across two categories: relative or absolute.&nbsp;&nbsp;&nbsp;</strong></p><p>In this webinar we will explore the importance of metabolomics in disease research, and the challenges associated with LC-MS based metabolomics studies. We will also introduce Pyxis, a scalable, machine learning-based approach to absolute quantitation of metabolites across various matrices, and potential applications in research and the clinic.&nbsp;</p><p><strong>Learning Objectives</strong></p><ul><li><strong>The application of quantitation in understanding metabolite functions in biological systems.</strong></li><li><strong>The experimental requirements of absolute and relative quantitation of metabolites along with their benefits and limitations.</strong></li><li><strong>Introduction of Pyxis, a method that enables scalable absolute quantitation of metabolites without relying on isotopically labeled standards.</strong></li></ul><blockquote><p><strong>Presenter:</strong> Naama Kanarek, PhD (Assistant Professor, Pathology Department at Boston Children’s Hospital and Harvard Medical School)</p><p>A native of Jerusalem, Israel, Dr. Naama Kanarek trained at the Hebrew University, where she earned a BSc in medical science, an MSc in proteomics and microbiology, and a PhD in immunology and cancer research (including one year at Columbia University Medical Center, NY). Dr. Kanarek’s postdoctoral research was performed under the supervision of Prof. David M. Sabatini at MIT’s Whitehead Institute.</p><p>Dr. Kanarek is the recipient of a number of awards and honors, including the Margaret and Herman Sokol Postdoctoral Award, the Leukemia and Lymphoma Society New Idea Award, the Hebrew University Women in Science Postdoctoral Award, the Weizmann Institute Postdoctoral Award for Advancing Women in Science and a Revson Fellow of that program, and the James Sivarsten Prize in Pediatric Cancer Research. Her postdoctoral work was supported by fellowships from the American Association for Cancer Research and the European Molecular Biology Organization.</p><p>Dr. Kanarek’s laboratory is interested in folate metabolism, and the metabolic adaptations of cells as they move around and migrate to new sites. They apply genetic perturbations, biochemical assays, molecular biology, functional genomic screens, and metabolite profiling by mass spectrometry in cell-culture systems and in vivo. They study basic folate biology including folate metabolism, folate-related signal transduction, the oncogenic role of folate and folate homeostasis in normal physiology and pathological conditions.</p><p><strong>Presenter:</strong> Jennifer M. Campbell, PhD (Chief Scientific Officer, Matterworks, Inc.)</p><p>Jennifer M. Campbell, PhD is currently Chief Scientific Officer at Matterworks, a multidisciplinary startup focused on using the power of deep learning on raw mass spectrometric data. Their first product, Pyxis, enables scalable quantitative metabolomics through the use of AI. Prior to Matterworks, Dr. Campbell worked at Novartis Institutes of Biomedical Research, heading up MS and separations within the Cambridge (MA) chemistry department. Dr. Campbell served as technical lead of NeoBase2, an FDA 510K approved assay for newborn screening at Perkin Elmer and Director of Proteomics at BG Medicine. Her career started in instrument development - she obtained her PhD, which focused on the development of a linear ion trap-TOFMS at the University of British Columbia under Don Douglas and she worked for eight years at Applied Biosystems, aiding in the development of all aspects of the MALDI TOF/TOF product line (4700, 4800, and 5800). She has authored numerous papers, patents, and book chapters.</p></blockquote></div>

The Analytical Scientist: A scalable approach to absolute quantitation in metabolomics

A scalable approach to absolute quantitation in metabolomics

We will explore the importance of metabolomics in disease research, and the challenges associated with LC-MS based metabolomics studies.

<div><div id="inner_content_body_text" data-content-id="391110"><p><strong>Per- and polyfluoroalkyl substances (PFAS) are synthetic chemicals prevalent across numerous industries and used in many everyday products, but their persistent and bioaccumulative nature raises critical health and environmental concerns. Join us for our upcoming Ask Me Anything (AMA) Q&amp;A session, where you can explore the latest research, regulatory challenges and advancements in the field.</strong></p><p>During this hour-long virtual session, you’ll have the unique opportunity to ask your most pressing questions directly to our expert speaker, Dr. Ian Ross, in real time.</p><h4><strong>About Our Expert</strong></h4><p>We are honored to host Dr. Ian Ross, Global PFAS Practice Lead at CDM Smith and visiting professor at Manchester Metropolitan University. Dr. Ross is a distinguished biochemist specializing in contaminated land assessment and PFAS decontamination. His extensive expertise is reflected in over 100 publications, including a comprehensive 204-page chapter on PFAS in the Emerging Contaminants Handbook.</p><h4><strong>What to Expect</strong></h4><p>Ian will connect with our live audience to address a broad spectrum of topics related to PFAS. While the spontaneous nature of an AMA session makes it impossible to predict every question, we anticipate discussions will focus on:</p><ul><li><strong>PFAS contamination:</strong> Latest research and case studies</li><li><strong>Environmental and health impacts:</strong> Emerging evidence and implications</li><li><strong>Regulatory challenges: </strong>Current frameworks and future directions</li><li><strong>Applications and concerns:</strong> Industrial uses and associated risks</li></ul><div><div><h4><strong>Why Attend?</strong></h4></div></div><ul><li><strong>Expert insights:</strong> Gain knowledge directly from a leading authority in PFAS.</li><li><strong>Live interaction:</strong> Have your questions addressed in real time for personalized answers.</li><li><strong>Exclusive content:</strong> Access in-depth discussions that you won't find anywhere else.</li></ul><p><strong>Space is limited! Register now to secure your spot for this exclusive AMA session.</strong></p><p><span><strong>Presenter:</strong> Ian Ross, PhD </span>(CDM Smith / Global PFAS Practice Lead, Manchester Metropolitan University)</p></div></div>

Technology Networks: Ask Me Anything: PFAS

Ask Me Anything: PFAS

Ian will connect with our live audience to address a broad spectrum of topics related to PFAS.

<div><div><div><p><strong>Alithea Biotechnology was founded in 2019 by Fanny Giannou and Tim Fugmann to support Biopharma globally on the development of innovative therapies targeting HLA-presented peptides. Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery.</strong></p><p>In addition, HLA-Compass is Alithea's cloud-accessible HLA peptide database featuring the measurement of a total of 1.4 Million HLA peptides in 4160 healthy tissue, tumor tissue and cancer cell line samples for target validation and off-target toxicity prediction.</p><h5><strong>Why to join this webinar:</strong></h5><ul><li><strong>The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample</strong></li><li><strong>Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process</strong></li><li><strong>The time is ripe to bring immunopeptidomics into clinical routine</strong></li></ul><blockquote><p><strong>Presenter:</strong> Tim Fugmann, Ph.D. (Chief Scientific Officer and Co-Founder, Alithea Biotechnology GmbH, Berlin, Germany)</p><p>Tim Fugmann got his Ph.D. from ETH Zurich, on mass-spectrometric discovery of antibody targets and disease biomarkers. Later, he was leading the target discovery efforts at Philochem, before moving to the Max-Delbrueck-Centrum for Molecular Medicine in Berlin. He was later appointed professor for MS-based proteomics at JLU Giessen. In 2019 he co-founded Alithea Bio UG, which is focusing on immunopeptidomics, a topic which Tim Fugmann studied since 2012.</p></blockquote></div></div></div>

Bruker: Unlocking the full potential of immunopeptidomics with the timsTOF Ultra

Unlocking the full potential of immunopeptidomics with the timsTOF Ultra

Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery.

The potential of immunopeptidomics with the timsTOF Ultra

<p><strong>Hear about the latest advancements in translational proteomics and metabolomics. From the molecular mechanisms of disease pathology to the latest technological developments in diagnostics and treatment.</strong></p><h5><strong>Key Learning Objectives:</strong></h5><ul><li>Spatial proteomics to assess health and diseases</li><li>Absolute quantitation of human proteins</li><li>The latest innovations in proteomics and metabolomics instrumentation and data analysis</li><li>Biomarker-guided precision medicine</li></ul><h4><strong>Day 1 – October 30</strong></h4><h5><strong>15:00 – 15:50 GMT: The Human Protein Atlas – Creating a Pan-Disease Resource Based on Next Generation Blood Profiling</strong></h5><ul><li>Mathias Uhlén, PhD (KTH Royal Institute of Technology)</li></ul><h5><strong>15:50 – 15:55 GMT:</strong> Networking Break</h5><h5><strong>15:55 – 16:15GMT: Mitigating Sorter-Induced Cellular Stress with Cartridge, Microfuildics-Based Sorting</strong></h5><ul><li>Crystal Montoya (Miltenyi Biotec)</li></ul><h5><strong>16:15 – 16:20 GMT:</strong> Networking Break</h5><h5><strong>16:20 – 16:40 GMT: Speaker to be announced</strong></h5><h5><strong>16:40 – 16:45 GMT</strong>: Networking Break</h5><h5><strong>16:45 – 17:35 GMT: Spatial Tissue Proteomics to Assess Health and Disease</strong></h5><ul><li>Fabian Coscia, PhD (Max Delbrück Center)</li></ul><h5><strong>17:35 – 17:40 GMT:</strong> Networking Break</h5><h5><strong>17:40 – 18:00 GMT: The Sulpho-Phospho-Vanillin Assay: Accurate Lipid Normalization in Quantitative Lipidomics</strong></h5><ul><li>Karri Basso, PhD (University of Florida)</li></ul><h5><strong>18:00 – 18:05 GMT:</strong> Networking Break</h5><h5><strong>18:05 – 18:55 GMT: Proteomics for Cancer Precision Medicine</strong></h5><ul><li>Janne Lehtiö, PhD (Karolinska Instutet)</li></ul><h5><strong>18:55 – 19:00 GMT: </strong>Networking Break</h5><h5><strong>19:00 – 19:20 GMT: How Breakthroughs in Depth, Scale and Speed are Unlocking New Proteomic Discovery</strong></h5><ul><li>Aaron Gajadhar, PhD (Seer Bio)</li></ul><h5><strong>19:20 – 19:25 GMT: </strong>Networking Break</h5><h5><strong>19:25 – 19:55 GMT:</strong> Phantom Metabolites: Unraveling Metabolic Shadows</h5><ul><li>Gary Siuzdak, PhD (Scripps Research Institute)</li></ul><h5><strong>19:55 GMT:</strong> End of Day 1</h5><div><div><div><h5><strong>Who Should Attend:</strong></h5><ul><li>Scientists and researchers seeking to expand their knowledge</li><li>Pharmaceutical and biotech professionals driving drug development</li><li>Clinicians looking to improve patient care</li><li>Academicians exploring new research avenues</li><li>Graduate students and postdoctoral fellows building their careers</li></ul><blockquote><p><strong>Presenter: </strong>Mathias Uhlén, PhD (Professor, KTH - Royal Institute of Technology)</p><p><strong>Presenter:&nbsp;</strong>Christoph Borchers, PhD (Professor, McGill University)</p><p><strong>Presenter:</strong>&nbsp;Janne Lehtiö, PhD (Professor, Karolinska Institutet)</p><p><strong>Presenter:</strong>&nbsp;Crystal Montoya (Senior Marketing Product Manager, Miltenyi Biotec)</p><p><strong>Presenter:</strong>&nbsp;Kari Basso, PhD (Director of Mass Spectrometry Research and Education, University of Florida)</p><p><strong>Presenter:&nbsp;</strong>Fabian Coscia, PhD (Group Leader, Max Delbrück Center)</p><p><strong>Presenter:</strong>&nbsp;Simone Sidoli, PhD (Assistant Professor, Albert Einstein College of Medicine)</p><p><strong>Presenter:</strong>&nbsp;Hagen Magnus Gegner, PhD (Content and Digital Marketing, CTC Analytics)</p><p><strong>Presenter:</strong>&nbsp;Matt Willetts, PhD (Proteomics Applications Manager, Bruker Daltonics)</p><p><strong>Presenter:&nbsp;</strong>Matteo Tardelli, PhD (Senior Biomarker Scientist, Owlstone Medical)</p><p><strong>Presenter:&nbsp;</strong>Aaron Gajadhar, PhD (Director, Strategic Applications, Seer)</p><p><strong>Presenter:&nbsp;</strong>Gary Siuzdak, PhD (Professor and Senior Director, Scripps Research Institute)</p></blockquote></div></div></div>

Technology Networks: Advances in Proteomics & Metabolomics 2024

Advances in Proteomics & Metabolomics 2024 (Day 1)

Hear about the latest advancements in translational proteomics and metabolomics. 

Advances in Proteomics & Metabolomics 2024  (Day 1)

<p><strong>Hear about the latest advancements in translational proteomics and metabolomics. From the molecular mechanisms of disease pathology to the latest technological developments in diagnostics and treatment.</strong></p><h5><strong>Key Learning Objectives:</strong></h5><ul><li>Spatial proteomics to assess health and diseases</li><li>Absolute quantitation of human proteins</li><li>The latest innovations in proteomics and metabolomics instrumentation and data analysis</li><li>Biomarker-guided precision medicine</li></ul><h4><strong>Day 2 – October 31</strong></h4><h5><strong>15:00 – 15:50 GMT: A Novel Strategy for the Absolute Quantification of Human Proteins</strong></h5><ul><li>Christoph Borchers, PhD (McGill University)</li></ul><h5><strong>15:50 – 15:55 GMT: </strong>Networking Break</h5><h5><strong>15:55 – 16:15 GMT: From Single Cells to the Metaproteome: Latest Developments in timsTOF Technology for Proteomics</strong></h5><ul><li>Matt Willetts, PhD (Bruker)</li></ul><h5><strong>16:15 – 16:20 GMT: </strong>Networking Break</h5><h5><strong>16:20 – 17:10 GMT: Single-Cell Chromatin Proteomics to Investigate the Biology of Exceptional Longevity</strong></h5><ul><li>Simone Sidoli, PhD (Albert Einstein College of Medicine)</li></ul><h5><strong>17:10 – 17:15 GMT: </strong>Networking Break</h5><h5><strong>17:15 – 17:35 GMT: Optimizing Metabolomics Workflows: From Sample Preparation to Multi-omics Integration</strong></h5><ul><li>Hagen Magnus Gegner, PhD (CTC Analytics)</li></ul><h5><strong>17:35 – 17:40 GMT:</strong> Networking Break</h5><h5><strong>17:40 – 18:10 GMT: Analyzing Metabolic Responses to a Standardized Meal Challenge Using Exhaled Breath</strong></h5><ul><li>Matteo Tardelli, PhD (Owlstone Medical)</li></ul><h5><strong>18:10 GMT: </strong>Event Close</h5><h5><strong>Who Should Attend:</strong></h5><ul><li>Scientists and researchers seeking to expand their knowledge</li><li>Pharmaceutical and biotech professionals driving drug development</li><li>Clinicians looking to improve patient care</li><li>Academicians exploring new research avenues</li><li>Graduate students and postdoctoral fellows building their careers</li></ul><blockquote><p><strong>Presenter: </strong>Mathias Uhlén, PhD (Professor, KTH - Royal Institute of Technology)</p><p><strong>Presenter:&nbsp;</strong>Christoph Borchers, PhD (Professor, McGill University)</p><p><strong>Presenter:</strong>&nbsp;Janne Lehtiö, PhD (Professor, Karolinska Institutet)</p><p><strong>Presenter:</strong>&nbsp;Crystal Montoya (Senior Marketing Product Manager, Miltenyi Biotec)</p><p><strong>Presenter:</strong>&nbsp;Kari Basso, PhD (Director of Mass Spectrometry Research and Education, University of Florida)</p><p><strong>Presenter:&nbsp;</strong>Fabian Coscia, PhD (Group Leader, Max Delbrück Center)</p><p><strong>Presenter:</strong>&nbsp;Simone Sidoli, PhD (Assistant Professor, Albert Einstein College of Medicine)</p><p><strong>Presenter:</strong>&nbsp;Hagen Magnus Gegner, PhD (Content and Digital Marketing, CTC Analytics)</p><p><strong>Presenter:</strong>&nbsp;Matt Willetts, PhD (Proteomics Applications Manager, Bruker Daltonics)</p><p><strong>Presenter:&nbsp;</strong>Matteo Tardelli, PhD (Senior Biomarker Scientist, Owlstone Medical)</p><p><strong>Presenter:&nbsp;</strong>Aaron Gajadhar, PhD (Director, Strategic Applications, Seer)</p><p><strong>Presenter:&nbsp;</strong>Gary Siuzdak, PhD (Professor and Senior Director, Scripps Research Institute)</p></blockquote>

Advances in Proteomics & Metabolomics 2024 (Day 2)

<div><div><div><p><strong>Pure MHC, a pioneer in immunopeptidomics, has partnered with Bruker, a leader in state-of-the-art mass spectrometry, to demonstrate one of Pure MHC’s immunopeptidomics workflows. In this Live from the Lab webinar, tissue sample processing, data acquisition with a Bruker timsTOF Ultra, and data analysis will be reviewed as tools for the development and validation of HLA peptide targets for immunopeptidomic development.</strong></p><p><strong>Key Learning Objectives:</strong></p><ul><li>Get insights into Pure MHC's sample preparation strategies to maximize the yield of immunopeptides from tissue samples</li><li>Discover how the unparalleled sensitivity and robustness of the Bruker timsTOF Ultra empowers users to maximize the potential of their immunopeptide samples</li><li>Understand data processing workflows for both DDA and DIA data processing</li></ul><blockquote><p><strong>Presenter:</strong> Curtis McMurtrey, Ph.D. (Director of Immunoproteomics, Pure MHC, LLC, Oklahoma City, OK, USA)</p><p>Dr. McMurtrey earned his Ph.D. in Microbiology and Immunology from the University of Oklahoma Health Sciences Center in 2010. He currently serves as the Director of Immuno-Proteomics at Pure MHC, LLC.</p><p>Dr. McMurtrey has studied HLA and its role in immunity since 2005. He is a member of American Society for Histocompatibility and Immunogenetics (ASHI) and holds the distinction of having won four ASHI Top Scholar Awards, more than any other scientist in the history of ASHI. Dr. McMurtrey is most notable for his work on West Nile virus epitope discovery and validation with HLA-A*02:01 and B*07:02; epitopes he discovered have been successfully tested in a WNV vaccine (collaboration with Drs. Hansen and Diamond at Washington University). His most recent accolades come from discovery of MR1 ligands from Mycobacterium tuberculosis (Mtb) as well as over 200 novel ligands from Toxoplasma gondii utilizing Deep Ligand Sequencing (DLS).</p><p>Dr. McMurtrey has expertise in BSL-3 containment techniques, protein purification, HLA ligand isolation, HPLC separation, mass spectrometric analysis, ELISPOT, and multicolor flow cytometry as well as provides bioinformatics expertise. To date, he has directed mass spectrometry (both IDA and SWATH) acquisition as well as comparative analysis and interpretation for a wide variety of MHC ligands including those from tuberculosis, toxoplasmosis, influenza, WNV, HIV and multiple cancers. Dr. Curtis McMurtrey oversees DLS acquisition and analyses and also manages database library collection.</p><p><strong>Presenter: </strong>Jason R. Krawic, Ph.D. (Business Development Manager, Pure MHC, LLC, Oklahoma City, OK, USA)</p><p>Dr. Krawic earned his Master’s degree in Biomolecular Sciences from Central Connecticut State University in 2012 before returning to academia and earning his Ph.D. in Microbiology and Immunology from the University of Oklahoma Health Sciences Center in 2024. He currently serves as the Director of Business Development at Pure MHC, LLC.</p><p>Dr. Krawic began his scientific career teaching Microbiology, Biology, and Chemistry to community college students in Connecticut and Oklahoma. He has studied HLA and non-classical MHC molecules since 2018. He is most recognized for discovering multiple isomeric conformations of MR1 ligands, as well as his work in MHC Class I and Class II ligands and cancer immunotherapies.</p><p>Dr. Krawic’s expertise ranges from classical microbiology and bacteriology to HPLC separation, protein purification, negative ion mode small molecule mass spectrometry, DDA, DIA and MRM acquisition and a variety of bioinformatics tools. In addition to his scientific career, Dr. Krawic has more than a decade of experience in sales and retail management. With this skill set he combines his science and sales backgrounds to serve Pure MHC’s customer base.</p><p><strong>Presenter: </strong>Kris Looney, MBA (President, Pure MHC, LLC, Austin, TX, USA)</p><p>As President of Emergent Technologies, the manager of Pure MHC, Kris Looney is responsible for conceiving and executing key business initiatives, developing strategic plans, and managing business processes including accounting, marketing, intellectual property, and business development. Kris has more than two decades of experience as a business generalist with a background in start-ups, management, accounting, marketing, negotiation, and sales.</p><p>Before joining Emergent, Kris served as the COO and Interim CEO of the American Red Cross of Central Texas, where he balanced multiple stakeholder needs with service responsibilities in a competitive philanthropic environment. Prior to that, he was the CFO of Transformation Enzyme Corporation, where his financial management and business development helped a bootstrapped entrepreneurial start-up become a leader in the nutritional supplement market. Kris has a B.A. in marketing and an M.B.A. from the University of Texas at Austin.</p><p><strong>Presenter: </strong>Matt Willetts, Ph.D. (Proteomics Applications Manager, Bruker Scientific LLC, Billerica, MA, USA)</p><p>Matt received his Ph.D. in mass spectrometry with Prof. Malcolm Clench at Sheffield Hallam University in the UK. He then joined Waters as the Technical Marketing Specialist for LCMS and MALDI products, focusing on application development for proteomics-based workflows. Matt joined Bruker in 2010 and is responsible for proteomics applications and support in North America.</p></blockquote><p>&nbsp;</p></div></div></div>

Bruker: Pure MHC's immunopeptidomics workflow with the timsTOF Ultra

Pure MHC's immunopeptidomics workflow with the timsTOF Ultra

Tissue sample processing, data acquisition with a Bruker timsTOF Ultra, and data analysis for immunopeptidomic development.

LCMS webinars focusing on LC/MS - page 39